Spots Global Cancer Trial Database for dacogen
Every month we try and update this database with for dacogen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00619099 | Myelodysplastic... | decitabine decitabine | 18 Years - | Eisai Inc. | |
| Trial of Decitabine in Patients With Acute Myeloid Leukemia | NCT00260832 | Acute Myeloid L... | Cytarabine or S... Dacogen (decita... | 65 Years - | Eisai Inc. | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome | NCT01400633 | Myelodysplastic... | decitabine inje... | 20 Years - | Janssen Korea, Ltd., Korea | |
| A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes | NCT00260065 | Myelodysplastic... | Decitabine | 18 Years - | Eisai Inc. | |
| An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) | NCT00744757 | Myelodysplastic... | Decitabine | 18 Years - | Johnson & Johnson Taiwan Ltd | |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | NCT00906334 | Myelodysplastic... | ON 01910.Na ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00760084 | Acute Myelogeno... Myelodysplastic... | Decitabine | 18 Years - | Eisai Inc. | |
| Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage | NCT04252248 | Head and Neck C... Anogenital Canc... | Dacogen | 18 Years - | University Hospital Heidelberg | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | NCT00791271 | Melanoma | Decitabine Pegylated Inter... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | NCT00358644 | Acute Myeloid L... | Decitabine | 60 Years - | Eisai Inc. | |
| Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | NCT02010645 | Leukemia | Eltrombopag Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | NCT01498445 | Leukemia | Dasatinib Decitabine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | NCT02469415 | Leukemia | Pacritinib 5-azacitidine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | NCT00414310 | Myelodysplastic... Acute Myelogeno... | Decitabine Valproic Acid | - | M.D. Anderson Cancer Center | |
| Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | NCT01794702 | Leukemia | Decitabine Idarubicin Cytarabine Clofarabine | 18 Years - 64 Years | M.D. Anderson Cancer Center | |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | NCT00561912 | Renal Cell Carc... | Decitabine Interferon Alfa... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) | NCT00067808 | Myelodysplastic... Chronic Myelomo... | Decitabine Decitabine Decitabine | - | M.D. Anderson Cancer Center | |
| Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | NCT01786343 | Leukemia | Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome | NCT01041846 | Myelodysplastic... | No intervention | 18 Years - | Janssen Korea, Ltd., Korea | |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT02141477 | Leukemia | Omacetaxine Decitabine | 70 Years - | M.D. Anderson Cancer Center | |
| A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome | NCT00282399 | Myelodysplastic... | Subcutaneous De... | 18 Years - | Eisai Inc. | |
| A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | NCT01853228 | Acute Myeloid L... | Phase1 and Phas... Phase 1: cytara... Phase 2: cytara... | 1 Month - 18 Years | Janssen Research & Development, LLC | |
| An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome | NCT01400633 | Myelodysplastic... | decitabine inje... | 20 Years - | Janssen Korea, Ltd., Korea | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) | NCT00882102 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) | NCT00358644 | Acute Myeloid L... | Decitabine | 60 Years - | Eisai Inc. | |
| Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | NCT01515527 | Leukemia | Cladribine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | NCT01786343 | Leukemia | Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome | NCT00968071 | Acute Myelogeno... Myelodysplastic... | Decitabine Gemtuzumab Ozog... | 16 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | NCT01993641 | Myelodysplastic... MDS | pracinostat Azacitidine Decitabine | 18 Years - | Helsinn Healthcare SA | |
| Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | NCT01893320 | Leukemia | Vosaroxin Decitabine | 60 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
